MEI Pharma, Inc. reported earnings results for the third quarter and nine months ended March 31, 2024. For the third quarter, the company reported net loss was USD 9.13 million compared to USD 15.44 million a year ago. Basic loss per share from continuing operations was USD 1.37 compared to USD 2.32 a year ago.
For the nine months, sales was USD 0.752 million compared to USD 47.36 million a year ago. Revenue was USD 65.3 million compared to USD 47.36 million a year ago. Net income was USD 36.18 million compared to net loss of USD 21.81 million a year ago. Basic earnings per share from continuing operations was USD 5.43 compared to basic loss per share from continuing operations of USD 3.27 a year ago.